Mucormycosis in Hematologic Malignancies

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Mucormycosis in Hematologic Malignancies trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT07185503

Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safe…

This clinical trial, a single-arm prospective study, aims to evaluate the efficacy and safety of liposomal amphotericin B (3-5 mg/kg/day) combined with posacona…

China60 participantsStarted 2025-03-25

Treatment: liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole

All recent trials (3 shown)

CompletedNot Applicable

NCT06900114

Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Co…

The project intends to carry out a retrospective study on the epidemiology, predisposing factors, clinical manifestations, diagnosis, treatment, prognosis and e…

China60 participantsStarted 2025-02-08

UnknownNot Applicable

NCT05925660

Mucorales PCR Screening in At-risk Hematology Patients

Patients with leukemia are treated with intensive chemotherapy and often have to undergo a stem cell transplantation which makes their immune system extremely v…

Belgium80 participantsStarted 2023-11-06

Treatment: Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)